ACT for Endometriosis in India: Immune Modulation and Tissue Repair | ALIV

Endometriosis — the condition where endometrial-like tissue grows outside the uterus, causing chronic pelvic pain, dysmenorrhoea, dyspareunia, and often infertility — affects an estimated 10–15% of reproductive-age women and remains one of gynaecology's most challenging management problems. Standard treatment (hormonal suppression, surgical excision) manages symptoms effectively in many patients but does not prevent recurrence after surgery — with recurrence rates of 30–50% at five years being well-documented. ALIV's Dr. Sunita Tandulwadkar applies ACT's immunomodulatory mechanism to endometriosis management as an adjunct to standard treatment — targeting the immune dysregulation that underlies endometriosis pathogenesis.

Endometriosis as an Immune Condition

Current understanding of endometriosis pathogenesis has shifted significantly toward immunological framing. In women with endometriosis, the normal immune surveillance that would clear refluxed endometrial cells from the peritoneal cavity is impaired — peritoneal macrophages are alternatively activated (M2 phenotype), natural killer cell activity is reduced, and regulatory T-cell function is altered, collectively creating a peritoneal immune environment that tolerates ectopic endometrial tissue attachment and growth. Chronic inflammation driven by these ectopic implants — producing elevated IL-1β, IL-6, TNF-α, and prostaglandins in the peritoneal fluid — sustains pain sensitisation, adhesion formation, and the progressive tissue involvement of the condition.

ACT's MSC-derived immunomodulatory signals — IL-10, TGF-β, IDO — target this immune dysregulation directly: promoting the shift from pro-inflammatory macrophage activity toward regulatory function; supporting natural killer cell restoration; and reducing the peritoneal inflammatory cytokine burden that drives pain and progressive lesion growth. The mechanism is analogous to ACT's role in IBD — a different immune dysregulation in a different tissue, but sharing the MSC immunomodulatory mechanism that has the most clinical plausibility. See: ACT for reproductive health.

Clinical Application and Expectations

ALIV's ACT for endometriosis is positioned as an adjunct to surgical management — not a replacement for laparoscopic excision of endometriotic implants, which remains the definitive treatment for established lesions. The clinical rationale for ACT in endometriosis is: post-surgical immune modulation to reduce the peritoneal inflammatory environment that drives recurrence; support for the pelvic floor and peritoneal tissue healing environment after surgery; and in infertility cases, improving the endometrial receptivity and pelvic inflammatory burden that impairs implantation. The evidence base for ACT specifically in endometriosis is emerging rather than established — this is an application where ALIV's clinical experience and mechanistic rationale provide the framework for carefully selected patients willing to engage with an experimental approach.

Can ACT replace surgery for endometriosis?

No — surgical excision of established endometriotic implants is necessary for patients with significant disease burden, and ACT does not produce direct removal of ectopic tissue. ACT's role is in the immune environment and post-surgical recurrence prevention context, not in replacing the mechanical resolution that surgery provides. Patients seeking to avoid surgery entirely may not be appropriate ACT candidates for this indication; the decision about whether ACT as sole management is appropriate requires individual assessment by Dr. Tandulwadkar based on stage, symptoms, and fertility goals.